Value Investor
Start free

Teladoc Health

TDOC on NYSE. Offices & clinics of doctors of medicine. Market value $1.1bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
12.4%very high

For every $100 of what the whole company costs, it produced $12.43 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 60 of 100. Price score: 33 of 100. Our list needs 70 on quality and 60 on price.

$5.79 a share, 32% above its 1-year low

Over the past year the price has ranged from $4.40 to $9.89.

Pays no dividend

Prices from Monday’s close (5 October).

Five years of cash, in billions

0.1
0.0
0.2
0.2
0.2
0.1
2021202220232024202512 monthsto Jun '26
Revenue
$2.0bn$2.4bn$2.6bn$2.6bn$2.5bn
Operating margin
-13.1%-567.3%-9.6%-39.7%-10.4%
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.16bn0.17bn0.17bn0.18bn0.18bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)4 of 8 checks we could run
  • Profit backed by cash (accruals)No
  • DebtUnknown
  • Revenue growth, five yearsStrong, 18.3% a year
  • Buying back its own sharesNo, 12% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $607 million last quarter, down 4% on a year ago.
  • A loss of $39 million, compared with a loss of $33 million a year ago.
  • It loses 7 cents on each $1 of sales, compared with 11 cents a year earlier.
  • Spare cash over the past 12 months: $131 million, down from $181 million.
  • 3% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in 1 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$641m
December 2024$640m
March 2025$629m
June 2025$632m
September 2025$626m
December 2025$642m
March 2026$614m
June 2026$607m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$33m
December 2024-$48m
March 2025-$93m
June 2025-$33m
September 2025-$50m
December 2025-$25m
March 2026-$64m
June 2026-$39m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
26 February 2026
Next quarterly (estimated, 10-Q)
29 October 2026

Who owns it

2 long-term investors we follow own it, up from 1 last quarter. 347 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

5 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $69,400 of shares on the open market. 6 sold $2m, $493,826 of it under preset trading plans.

  • DIVITA CHARLES III
    CHIEF EXECUTIVE OFFICER, Director
    Sold
    Date
    11 September 2026
    Shares
    17,805
    Price
    $6.10
    Value
    $108,682
  • Rodrigues Fernando M.
    President of BetterHelp
    Sold
    under a preset trading plan
    Date
    3 September 2026
    Shares
    9,812
    Price
    $6.51
    Value
    $63,876
  • Nueno Carlos
    President, International
    Sold
    Date
    2 September 2026
    Shares
    6,200
    Price
    $6.30
    Value
    $39,066
  • Rodrigues Fernando M.
    President of BetterHelp
    Sold
    under a preset trading plan
    Date
    2 September 2026
    Shares
    5,439
    Price
    $6.30
    Value
    $34,271
  • Bliss Kelly
    President, U.S. Group Health
    Sold
    Date
    2 September 2026
    Shares
    7,357
    Price
    $6.30
    Value
    $46,356
  • Catapano Joseph Ronald
    Chief Accounting Officer
    Sold
    Date
    2 September 2026
    Shares
    274
    Price
    $6.30
    Value
    $1,726
  • Vandervoort Adam C
    CHIEF LEGAL OFFICER, SECRETARY
    Sold
    Date
    2 September 2026
    Shares
    7,573
    Price
    $6.30
    Value
    $47,717
  • DIVITA CHARLES III
    CHIEF EXECUTIVE OFFICER, Director
    Sold
    Date
    2 September 2026
    Shares
    18,327
    Price
    $6.30
    Value
    $115,478
  • Bliss Kelly
    President, U.S. Group Health
    Sold
    under a preset trading plan
    Date
    6 July 2026
    Shares
    2,500
    Price
    $9.50
    Value
    $23,750
  • Catapano Joseph Ronald
    Chief Accounting Officer
    Sold
    Date
    2 July 2026
    Shares
    653
    Price
    $9.10
    Value
    $5,942

From Form 4 filings: insiders must report trades in their own company's shares within two days.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.